Futu Holdings Limited Sponsored ADR (FUTU) closed the last trading session at $171.45, gaining 3.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $218.57 indicates a 27.5% upside potential.The mean estimate comprises 11 short-term price targets with a standard deviation of $34.89. While the lowest estimate of $157.85 indicates a 7.9% decline from the current price level, the most ...

IHS Holding (IHS) closed the last trading session at $7.35, gaining 17.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.63 indicates a 31% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $3.51. While the lowest estimate of $6.00 indicates a 18.4% decline from the current price level, the most optimistic analyst expects t ...

Amicus Therapeutics (FOLD) closed the last trading session at $9.9, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.9 indicates a 60.6% upside potential.The average comprises 10 short-term price targets ranging from a low of $11.00 to a high of $21.00, with a standard deviation of $3.35. While the lowest estimate indicates an increase of 11.1% from the current pric ...

Marvell Technology (MRVL) closed the last trading session at $89.43, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $114.7 indicates a 28.3% upside potential.The mean estimate comprises 33 short-term price targets with a standard deviation of $22.86. While the lowest estimate of $58.20 indicates a 34.9% decline from the current price level, the most optimistic analyst ...

Core Viewpoint - Omnicom (OMC) has shown a 4.5% increase in stock price over the past four weeks, with a mean price target of $97.38 indicating a potential upside of 25.8% from the current price of $77.42 [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $11.5, suggesting variability in analyst predictions. The lowest estimate is $82.00 (5.9% increase), while the highest is $115.00 (48.5% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction and magnitude, serving as a starting point for further research [9] Group 2: Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding OMC's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11] - Over the last 30 days, one earnings estimate has increased, leading to a 0.5% rise in the Zacks Consensus Estimate for the current year [12] Group 3: Zacks Rank and Investment Potential - OMC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for price movement direction [14]

Core Viewpoint - CVS Health Corporation is experiencing a positive outlook from various analysts, with multiple price target upgrades suggesting significant growth potential in the healthcare sector [2][3][4]. Analyst Ratings and Price Targets - Kevin Caliendo from UBS set a price target of $97 for CVS, indicating a potential increase of approximately 24% from its current price of $78.24 [2][6]. - Wolfe Research raised its price target from $85 to $100, reflecting strong market sentiment towards CVS [2][6]. - Leerink Partners increased their price objective from $86 to $95, maintaining an "outperform" rating [3]. - Evercore ISI also raised their price target from $85 to $95, assigning an "outperform" rating [3]. Market Sentiment and Stock Performance - Despite the positive outlook from several analysts, Zacks Research downgraded CVS from a "strong-buy" to a "hold" rating, indicating some caution in the market [4][6]. - The stock's current price of $78.24 reflects a 2.23% increase, with a trading volume of 12.58 million shares on the NYSE [4]. - CVS's market capitalization is approximately $99.32 billion, highlighting its significant presence in the healthcare industry [5]. Stock Volatility - The stock has fluctuated between a low of $78.22 and a high of $80.50 today, with a 52-week range of $43.56 to $85.15, indicating dynamic market conditions [5].

Prestige Consumer Healthcare (PBH) closed the last trading session at $60.82, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $76.67 indicates a 26.1% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $9.87. While the lowest estimate of $70.00 indicates a 15.1% increase from the current price level, the most optimi ...

Group 1 - Five9 (FIVN) closed at $20.65, with a 4.1% gain over the past four weeks, and a mean price target of $33.95 suggests a 64.4% upside potential [1] - The mean estimate consists of 20 short-term price targets with a standard deviation of $8.77, indicating variability among analysts; the lowest estimate is $22.00 (6.5% increase), while the highest is $59.00 (185.7% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 25.4% over the last 30 days [11][12] Group 2 - FIVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of the stock's potential gain, but it does imply a positive direction for price movement [14]

Core Viewpoint - Certara, Inc. (CERT) shows potential for significant upside, with a mean price target of $13.21 indicating a 43.3% increase from the current price of $9.22 [1] Price Targets and Analyst Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $2.59, indicating variability among analysts; the lowest estimate is $9.00 (2.4% decline), while the highest is $16.00 (73.5% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about Certara's earnings prospects, as indicated by a positive trend in earnings estimate revisions; three estimates have increased over the last 30 days, leading to a 10.9% rise in the Zacks Consensus Estimate [11][12] - Certara holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead; empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Shares of NetScout Systems (NTCT) have gained 1.5% over the past four weeks to close the last trading session at $27.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $36.33 indicates a potential upside of 33%.The mean estimate comprises three short-term price targets with a standard deviation of $6.11. While the lowest estimate of $31.00 indicates a 13.5% increase from the cu ...